Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
PLoS One. 2011 Mar 31;6(3):e18273. doi: 10.1371/journal.pone.0018273.
The Kv11.1 (hERG) K+ channel plays a fundamental role in cardiac repolarization. Missense mutations in KCNH2, the gene encoding Kv11.1, cause long QT syndrome (LQTS) and frequently cause channel trafficking-deficiencies. This study characterized the properties of a novel KCNH2 mutation discovered in a LQT2 patient resuscitated from a ventricular fibrillation arrest. Proband genotyping was performed by SSCP and DNA sequencing. The electrophysiological and biochemical properties of the mutant channel were investigated after expression in HEK293 cells. The proband manifested a QTc of 554 ms prior to electrolyte normalization. Mutation analysis revealed an autosomal dominant frameshift mutation at proline 1086 (P1086fs+32X; 3256InsG). Co-immunoprecipitation demonstrated that wild-type Kv11.1 and mutant channels coassemble. Western blot showed that the mutation did not produce mature complex-glycosylated Kv11.1 channels and coexpression resulted in reduced channel maturation. Electrophysiological recordings revealed mutant channel peak currents to be similar to untransfected cells. Co-expression of channels in a 1∶1 ratio demonstrated dominant negative suppression of peak Kv11.1 currents. Immunocytochemistry confirmed that mutant channels were not present at the plasma membrane. Mutant channel trafficking rescue was attempted by incubation at reduced temperature or with the pharmacological agents E-4031. These treatments did not significantly increase peak mutant currents or induce the formation of mature complex-glycosylated channels. The proteasomal inhibitor lactacystin increased the protein levels of the mutant channels demonstrating proteasomal degradation, but failed to induce mutant Kv11.1 protein trafficking. Our study demonstrates a novel dominant-negative Kv11.1 mutation, which results in degraded non-functional channels leading to a LQT2 phenotype.
Kv11.1 (hERG) K+ 通道在心脏复极中发挥着基本作用。编码 Kv11.1 的 KCNH2 基因中的错义突变导致长 QT 综合征 (LQTS),并经常导致通道转运缺陷。本研究对从心室颤动骤停中复苏的 LQT2 患者中发现的一种新型 KCNH2 突变进行了特征描述。通过 SSCP 和 DNA 测序对先证者进行基因分型。在 HEK293 细胞中表达后,研究了突变通道的电生理和生化特性。先证者在电解质正常化之前表现出 QTc 为 554 ms。突变分析显示在脯氨酸 1086 处存在常染色体显性移码突变(P1086fs+32X;3256InsG)。共免疫沉淀表明野生型 Kv11.1 和突变通道共同组装。Western blot 显示该突变不会产生成熟的复合糖基化 Kv11.1 通道,并且共表达导致通道成熟减少。电生理记录显示突变通道的峰值电流与未转染细胞相似。以 1∶1 的比例共表达通道显示对峰值 Kv11.1 电流的显性负抑制。免疫细胞化学证实突变通道不存在于质膜上。通过在较低温度下孵育或用药理学试剂 E-4031 尝试突变通道转运挽救,但这并没有显著增加峰值突变电流或诱导成熟的复合糖基化通道的形成。蛋白酶体抑制剂乳胞素增加了突变通道的蛋白水平,表明蛋白酶体降解,但未能诱导突变 Kv11.1 蛋白转运。我们的研究表明了一种新型的显性负性 Kv11.1 突变,导致降解的非功能性通道导致 LQT2 表型。